Free Trial
NASDAQ:BRTX

Biorestorative Therapies 6/11/2024 Earnings Report

Biorestorative Therapies logo
$1.63 -0.04 (-2.46%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Biorestorative Therapies EPS Results

Actual EPS
-$0.53
Consensus EPS
-$0.51
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Biorestorative Therapies Revenue Results

Actual Revenue
$0.04 million
Expected Revenue
$0.03 million
Beat/Miss
Beat by +$10.00 thousand
YoY Revenue Growth
N/A

Biorestorative Therapies Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Biorestorative Therapies' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled on Wednesday, November 12, 2025 at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Biorestorative Therapies Earnings Headlines

1 Hour Once A Day
My top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to help regular investors generate enough income to become financially independent… Without taking on excessive amounts of risk. I’m talking about having the opportunity to collect $500 on Monday… $563 on Wednesday… Then as much as $625 on Friday.tc pixel
Earnings Outlook For BioRestorative Therapies
See More Biorestorative Therapies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biorestorative Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biorestorative Therapies and other key companies, straight to your email.

About Biorestorative Therapies

Biorestorative Therapies (NASDAQ:BRTX) Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy. Biorestorative Therapies’ candidate has completed early-stage clinical evaluation and is advancing through planned trials to assess safety and efficacy in reducing the duration and severity of oral mucositis. Preclinical studies have also been conducted to explore additional indications, including inflammatory and degenerative conditions.

Headquartered in Malvern, Pennsylvania, Biorestorative Therapies manages its research, manufacturing and clinical development activities in the United States. The company works with clinical research organizations and academic centers to support its ongoing trials and maintains a leadership team with experience spanning cell therapy, clinical development and regulatory affairs. Biorestorative Therapies continues to pursue partnerships to expand its pipeline and accelerate the path to potential regulatory approval.

View Biorestorative Therapies Profile

More Earnings Resources from MarketBeat